Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Martin Almquist

Showing results (21-30 of 132) with videos related to

Pageof 14
Sort By:
Langenbeck'S Archives of Surgery|September 22, 2011
Determinants for malignancy in surgically treated adrenal lesionsLucie Wright, Erik Nordenström, Martin Almquist
Head & Neck|December 21, 2016
Reply to letter to the editor regarding cardiac arrest after vagal stimulation in intraoperative neuromonitoringMartin Almquist, M Thier, F Salem
Langenbeck'S Archives of Surgery|January 3, 2018
Predictors of multiglandular disease in primary hyperparathyroidismMark Thier, Sébastien Daudi, Anders Bergenfelz, et al.
Cancer Causes & Control : CCC|March 30, 2016
Vitamin D, PTH, and calcium in relation to survival following prostate cancerJohan Brändstedt, Martin Almquist, Jonas Manjer, et al.
Clinical and Experimental Nephrology|February 26, 2018
Is low pre-transplant parathyroid hormone a risk marker for cardiovascular disease in long-term follow-up of renal transplant recipients?Elin Isaksson, Martin Almquist, Astrid Seeberger, et al.
Cancer Causes & Control : CCC|June 19, 2012
Vitamin D, PTH, and calcium and the risk of prostate cancer: a prospective nested case-control studyJohan Brändstedt, Martin Almquist, Jonas Manjer, et al.
Patient Preference and Adherence|November 8, 2019
Patient And Nurse Experience Of Using Somatostatin Analogues To Treat Gastroenteropancreatic Neuroendocrine Tumors: Results Of The Somatostatin Treatment Experience Trial (STREET)Torbjörn Ström, Gordana Kozlovacki, Peter Myrenfors, et al.
BJS Open|December 9, 2021
Optimization of follow-up in patients with papillary thyroid cancer who show no evidence of disease 9-12 months after treatmentFabian Nordell, Ghadir Hallal, Pernilla Asp, et al.
BJS Open|January 9, 2022
Corrigendum to: Optimisation of follow-up in patients with papillary thyroid cancer who show no evidence of disease 9 to 12 months after treatmentFabian Nordell, Ghadir Hallal, Pernilla Asp, et al.
BMC Nephrology|January 24, 2025
Survival in patients with CKD 3-5 after 12 months of exercise training - a post-hoc analysis of the RENEXC trialSara Denguir, Matthias Hellberg, Martin Almquist, et al.
Pageof 14

Showing results (21-30 of 132) with videos related to

Sort By:
Pageof 14
Langenbeck'S Archives of Surgery|September 22, 2011
Determinants for malignancy in surgically treated adrenal lesionsLucie Wright, Erik Nordenström, Martin Almquist
Head & Neck|December 21, 2016
Reply to letter to the editor regarding cardiac arrest after vagal stimulation in intraoperative neuromonitoringMartin Almquist, M Thier, F Salem
Langenbeck'S Archives of Surgery|January 3, 2018
Predictors of multiglandular disease in primary hyperparathyroidismMark Thier, Sébastien Daudi, Anders Bergenfelz, et al.
Cancer Causes & Control : CCC|March 30, 2016
Vitamin D, PTH, and calcium in relation to survival following prostate cancerJohan Brändstedt, Martin Almquist, Jonas Manjer, et al.
Clinical and Experimental Nephrology|February 26, 2018
Is low pre-transplant parathyroid hormone a risk marker for cardiovascular disease in long-term follow-up of renal transplant recipients?Elin Isaksson, Martin Almquist, Astrid Seeberger, et al.
Cancer Causes & Control : CCC|June 19, 2012
Vitamin D, PTH, and calcium and the risk of prostate cancer: a prospective nested case-control studyJohan Brändstedt, Martin Almquist, Jonas Manjer, et al.
Patient Preference and Adherence|November 8, 2019
Patient And Nurse Experience Of Using Somatostatin Analogues To Treat Gastroenteropancreatic Neuroendocrine Tumors: Results Of The Somatostatin Treatment Experience Trial (STREET)Torbjörn Ström, Gordana Kozlovacki, Peter Myrenfors, et al.
BJS Open|December 9, 2021
Optimization of follow-up in patients with papillary thyroid cancer who show no evidence of disease 9-12 months after treatmentFabian Nordell, Ghadir Hallal, Pernilla Asp, et al.
BJS Open|January 9, 2022
Corrigendum to: Optimisation of follow-up in patients with papillary thyroid cancer who show no evidence of disease 9 to 12 months after treatmentFabian Nordell, Ghadir Hallal, Pernilla Asp, et al.
BMC Nephrology|January 24, 2025
Survival in patients with CKD 3-5 after 12 months of exercise training - a post-hoc analysis of the RENEXC trialSara Denguir, Matthias Hellberg, Martin Almquist, et al.
Pageof 14